COVID-19 /SARS-CoV2 update
In view of the recent development of the COVID-19 pandemic, we would like to inform you that our facility remains fully operational under safe work environment guidelines and that
all studies are performed as scheduled. We do not expect any reduction of our service capacity and are happy to discuss any project with you. Please reach out!
Jens Hoffmann (CEO)
extensively characterized patient derived xenografts
for applied studies (preclinical phase II)
implementation of individualized therapy
large panels of tumor models
corresponding repositories of tumor material
(OTC, snap frozen, FFPE, DNA, RNA)
extensive data about histology, genetic profile
and drug sensitivity
tumor models with defined target expression for screening and comparison with standards
implementation of transgenic techniques
EXPERIMENTAL PATHOLOGY -
HISTOPATHOLOGY @ EPO
pathology diagnostic service for laboratory rodents and lagomorphs
histopathology and gross pathology
immunohistochemistry / immunofluorescence
More than 500 well characterized PDX, xenografts, syngeneic and humanized tumor models available.
For access to our tumor model repository please send us an
Based on a more than 20 years experience, EPO offers customized and comprehensive service for the preclinical development of new cancer drugs.
EPO is offering experimental pathology and histopathology services.
2019 © EPO Berlin-Buch GmbH